Navigation Links
Vion Pharmaceuticals Holds Special Meeting of Stockholders
Date:2/13/2008

Stockholders Approve Board Authority to Implement Reverse Stock Split and

Reduce the Number of Total Shares and Authorized Shares

NEW HAVEN, Conn., Feb. 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced that a Special Meeting of Stockholders was held at the Omni Hotel in New Haven, Connecticut today at 10:00 Eastern Time.

At the meeting, shareholders voted to approve amendments to the Company's Restated Certificate of Incorporation to:

-- effect a reverse stock split of the Company's outstanding common stock

of not less than 1-for-5 and not more than 1-for-10, with the exact

ratio to be set within that range by the Board of Directors without

further approval by stockholders; and

-- decrease the total number of shares and the number of shares of common

stock that the Company is authorized to issue.

Alan Kessman, Chief Executive Officer, said, "We are pleased that our shareholders have authorized our Board of Directors to implement a reverse stock split. We will now determine the appropriate split ratio to establish a price for our common stock allowing us to regain compliance with Nasdaq's listing requirements."

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... LA (PRWEB) August 01, 2014 Chantel Lee ... conduct research for 10 40-hour weeks with Dr. Juan Rodriguez, ... of diabetic retinopathy, a common diabetic eye disease caused by ... , "What Chantel and Eli accomplished is quite remarkable,” said ... only a concept when they started, and together carried it ...
(Date:8/1/2014)... As one of the 10 largest medical ... & Clinical Lab Expo is the place where breakthrough ... to the healthcare world. This year, many of the ... include the latest diagnostic technology in the field of ... biosensors have enabled the development of "labs-on-a-chip" that can ...
(Date:8/1/2014)... 1, 2014 Research and Markets ... Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism (SNP) genotyping ... SNPs in the genome of various species. SNPs are ... and analysis technology can analyze thousands of SNPs and ...
(Date:8/1/2014)... August 01, 2014 Testing the ... to a better understanding embryonic development. How ... into structurally and functionally distinct tissues is important ... Prof. Todd McDevitt, Melissa Kinney, and Rabbia ... interact with biochemical cues to control many aspects ...
Breaking Biology Technology:Two Centenary College Students Tackle Diabetic Retinopathy Research 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Study Links Biomechanics and Gene Expression in Stem Cells 2
... Oriental,Bioengineering, Inc. (NYSE: AOB ), a pharmaceutical ... and commercialization,of a broad range of prescription and ... the following statement regarding the earthquake in,China:, ... China,s earthquake and we,are thankful to report that ...
... EAST RUTHERFORD, N.J., May 15 Cambrex (NYSE:,CBM), a ... of,Directors appointed Steven M. Klosk, President and Chief Executive ... Directors effective May,14, 2008. James A. Mack, President and ... announced he will step down. The Company will,separate the ...
... PRINCETON, N.J., May 15 Derma Sciences, Inc.,(OTC ... results today for the first quarter ended March 31, ... the previous year, including sales,from the newly acquired First ... guidance, due primarily to higher than expected,integration costs associated ...
Cached Biology Technology:American Oriental Bioengineering Comments on Earthquake 2Cambrex Appoints Steven M. Klosk as President and CEO 2Derma Sciences Reports First Quarter 2008 Results 2Derma Sciences Reports First Quarter 2008 Results 3Derma Sciences Reports First Quarter 2008 Results 4Derma Sciences Reports First Quarter 2008 Results 5
(Date:7/31/2014)... the largest minority group in the United States, comprising ... are obese and are 1.2 times as likely to ... College of Nursing student researcher Lauren Gerchow, BSN, RN, ... contribute to this problem by compiling a systematic review ... Latina women recently published in Nursing Research . ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... COLUMBUS , Ohio -- As sea levels rise, coastal communities ... water supplies than previously thought, according to a new study ... saltwater will intrude into fresh water aquifers, given the sea ... (IPCC). The IPCC has concluded that within the next 100 ...
... In a recent academic review, a University of Minnesota professor ... as opposed to specific nutrients, may be key to having ... practice in food industry and government, where marketers and regulators ... on specific vitamins and added supplements in food products, not ...
... produce lubricin, a thin film of protein found in ... friction in their joints, a new study led by ... friction and early wear in joints is a first; ... before. The finding, published in Arthritis & Rheumatism, sheds ...
Cached Biology News:Climate change could diminish drinking water more than expected 2Climate change could diminish drinking water more than expected 3Foods, not specific nutrients, may be key to good health 2First-ever study: lack of critical lubricant causes wear in joints 2
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: